In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Galectin Therapeutics Inc.

http://www.galectintherapeutics.com

Latest From Galectin Therapeutics Inc.

Asia Deal Watch: Cancer Collaborations, Licensings Lead Activity In Asia

Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.

Deals Business Strategies

Protein Degradation Leader Nurix Prepares First Clinical Trial

After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.

Companies Commercial

NeuroPace Raises $67M To Help Commercialize RNS System For Epilepsy

The latest financing round will also support a new clinical trial of the RNS system for children with epilepsy.

Financing Commercial

Eylea Biosimilar Race Hots Up As Formycon Launches Phase III Trials

Formycon has pushed its second ophthalmology biosimilar candidate into Phase III trials, the German firm’s Eylea (aflibercept) biosimilar, FYB203, which has been licensed to Bioeq. Multiple firms are now circling Eylea, ahead of a projected US market formation in 2023.

Clinical Trials Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Other Names / Subsidiaries
    • Galectin Sciences, LLC
    • Pro-Pharmaceuticals Inc.
    • Galectin Therapeutics Security Corp.
UsernamePublicRestriction

Register